Literature DB >> 27371725

ERAAP Shapes the Peptidome Associated with Classical and Nonclassical MHC Class I Molecules.

Niranjana A Nagarajan1, Danielle A de Verteuil2, Dev Sriranganadane2, Wafaa Yahyaoui2, Pierre Thibault2, Claude Perreault2, Nilabh Shastri1.   

Abstract

The peptide repertoire presented by classical as well as nonclassical MHC class I (MHC I) molecules is altered in the absence of the endoplasmic reticulum aminopeptidase associated with Ag processing (ERAAP). To characterize the extent of these changes, peptides from cells lacking ERAAP were eluted from the cell surface and analyzed by high-throughput mass spectrometry. We found that most peptides found in wild-type (WT) cells were retained in the absence of ERAAP. In contrast, a subset of "ERAAP-edited" peptides was lost in WT cells, and ERAAP-deficient cells presented a unique "unedited" repertoire. A substantial fraction of MHC-associated peptides from ERAAP-deficient cells contained N-terminal extensions and had a different molecular composition than did those from WT cells. We found that the number and immunogenicity of peptides associated with nonclassical MHC I was increased in the absence of ERAAP. Conversely, only peptides presented by classical MHC I were immunogenic in ERAAP-sufficient cells. Finally, MHC I peptides were also derived from different intracellular sources in ERAAP-deficient cells.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27371725      PMCID: PMC4976029          DOI: 10.4049/jimmunol.1500654

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Molecular mimicry mediated by MHC class Ib molecules after infection with gram-negative pathogens.

Authors:  W F Lo; A S Woods; A DeCloux; R J Cotter; E S Metcalf; M J Soloski
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 2.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

3.  Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules.

Authors:  Danielle de Verteuil; Tara L Muratore-Schroeder; Diana P Granados; Marie-Hélène Fortier; Marie-Pierre Hardy; Alexandre Bramoullé; Etienne Caron; Krystel Vincent; Sylvie Mader; Sébastien Lemieux; Pierre Thibault; Claude Perreault
Journal:  Mol Cell Proteomics       Date:  2010-05-19       Impact factor: 5.911

4.  Prediction of peptide-MHC binding using profiles.

Authors:  Pedro A Reche; Ellis L Reinherz
Journal:  Methods Mol Biol       Date:  2007

5.  Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen.

Authors:  C J Aldrich; A DeCloux; A S Woods; R J Cotter; M J Soloski; J Forman
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

6.  Alternative peptide binding motifs of Qa-2 class Ib molecules define rules for binding of self and nonself peptides.

Authors:  P Tabaczewski; E Chiang; M Henson; I Stroynowski
Journal:  J Immunol       Date:  1997-09-15       Impact factor: 5.422

Review 7.  Pathways of antigen processing.

Authors:  Janice S Blum; Pamela A Wearsch; Peter Cresswell
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

8.  In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules.

Authors:  Jingbo Yan; Vrajesh V Parekh; Yanice Mendez-Fernandez; Danyvid Olivares-Villagómez; Srdjan Dragovic; Timothy Hill; Derry C Roopenian; Sebastian Joyce; Luc Van Kaer
Journal:  J Exp Med       Date:  2006-02-27       Impact factor: 14.307

9.  The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects.

Authors:  Cláudia C Oliveira; Peter A van Veelen; Bianca Querido; Arnoud de Ru; Marjolein Sluijter; Sandra Laban; Jan W Drijfhout; Sjoerd H van der Burg; Rienk Offringa; Thorbald van Hall
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

10.  The MHC class I peptide repertoire is molded by the transcriptome.

Authors:  Marie-Hélène Fortier; Etienne Caron; Marie-Pierre Hardy; Grégory Voisin; Sébastien Lemieux; Claude Perreault; Pierre Thibault
Journal:  J Exp Med       Date:  2008-02-25       Impact factor: 14.307

View more
  16 in total

1.  Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).

Authors:  Despoina Koumantou; Eilon Barnea; Adrian Martin-Esteban; Zachary Maben; Athanasios Papakyriakou; Anastasia Mpakali; Paraskevi Kokkala; Harris Pratsinis; Dimitris Georgiadis; Lawrence J Stern; Arie Admon; Efstratios Stratikos
Journal:  Cancer Immunol Immunother       Date:  2019-06-20       Impact factor: 6.968

2.  Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-associated HLA-B*51 Peptidome.

Authors:  Pablo Guasp; Elena Lorente; Adrian Martín-Esteban; Eilon Barnea; Paolo Romania; Doriana Fruci; JonasJ W Kuiper; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2019-05-15       Impact factor: 5.911

3.  The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion.

Authors:  Eilon Barnea; Dganit Melamed Kadosh; Yael Haimovich; Nimman Satumtira; Martha L Dorris; Mylinh T Nguyen; Robert E Hammer; Tri M Tran; Robert A Colbert; Joel D Taurog; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2017-02-10       Impact factor: 5.911

4.  Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1.

Authors:  Zachary Maben; Richa Arya; Digamber Rane; W Frank An; Shailesh Metkar; Marc Hickey; Samantha Bender; Akbar Ali; Tina T Nguyen; Irini Evnouchidou; Roger Schilling; Efstratios Stratikos; Jennifer Golden; Lawrence J Stern
Journal:  J Med Chem       Date:  2019-12-30       Impact factor: 7.446

5.  ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism.

Authors:  Alina Steinbach; Jan Winter; Miriam Reuschenbach; Renata Blatnik; Alexandra Klevenz; Miriam Bertrand; Stephanie Hoppe; Magnus von Knebel Doeberitz; Agnieszka K Grabowska; Angelika B Riemer
Journal:  Oncoimmunology       Date:  2017-06-20       Impact factor: 8.110

Review 6.  Molecular pathways for antigenic peptide generation by ER aminopeptidase 1.

Authors:  Anastasia Mpakali; Zachary Maben; Lawrence J Stern; Efstratios Stratikos
Journal:  Mol Immunol       Date:  2018-04-17       Impact factor: 4.407

Review 7.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.

Authors:  Suchit Jhunjhunwala; Christian Hammer; Lélia Delamarre
Journal:  Nat Rev Cancer       Date:  2021-03-09       Impact factor: 60.716

8.  A systematic re-examination of processing of MHCI-bound antigenic peptide precursors by endoplasmic reticulum aminopeptidase 1.

Authors:  George Mavridis; Richa Arya; Alexander Domnick; Jerome Zoidakis; Manousos Makridakis; Antonia Vlahou; Anastasia Mpakali; Angelos Lelis; Dimitris Georgiadis; Robert Tampé; Athanasios Papakyriakou; Lawrence J Stern; Efstratios Stratikos
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

9.  Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration.

Authors:  Yoong Wearn Lim; Haiyin Chen-Harris; Oleg Mayba; Steve Lianoglou; Arthur Wuster; Tushar Bhangale; Zia Khan; Sanjeev Mariathasan; Anneleen Daemen; Jens Reeder; Peter M Haverty; William F Forrest; Matthew Brauer; Ira Mellman; Matthew L Albert
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-21       Impact factor: 11.205

Review 10.  The nonclassical immune surveillance for ERAAP function.

Authors:  Jian Guan; Josiah David Peske; Joshua A Taylor; Nilabh Shastri
Journal:  Curr Opin Immunol       Date:  2021-06-05       Impact factor: 7.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.